Physician profile
Alyson Salling
NPI 1508354473
$968.96
in general payments reported to CMS, 2019-2025
21 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $130 · 2023: $137 · 2024: $172 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $111.03 | 2025 | |
| Mayne Pharma Commercial LLC | $102.83 | 2023-2025 | |
| Hologic Sales and Service, LLC | $98.33 | 2023-2025 | Aptima |
| Abbvie INC. | $76.90 | 2021 | |
| Organon LLC | $69.52 | 2022-2025 | Jada System, Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $66.91 | 2023-2025 | |
| Evofem Biosciences, INC. | $56.02 | 2022-2025 | Phexxi, Solosec, Phexx |
| Astellas Pharma US INC | $55.29 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $47.76 | 2023-2025 | Myfembree, Gemtesa |
| Mylan Pharmaceuticals INC. | $46.70 | 2021-2022 | |
| Scynexis, INC. | $39.24 | 2022 | |
| Pfizer INC. | $30.93 | 2022 | |
| Novo Nordisk INC | $28.50 | 2021 | |
| Dexcom, INC. | $23.12 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $22.12 | 2025 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.52 | 2021 | |
| Medtronic, INC. | $17.50 | 2025 | Truclear |
| Shield Therapeutics INC | $16.89 | 2023 | Accrufer |
| Lilly USA, LLC | $13.81 | 2021 | |
| Merck Sharp & Dohme LLC | $13.33 | 2021 | |
| Myovant Sciences INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyson Salling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.